ALZ (ALZ) News
Follow ALZ (ALZ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Alzinova AB (ALZ) Completes Study Backing Blood-Based Alzheimer’s Test
Alzinova completed its Amsterdam UMC study, showing measurable serum antibodies and lower reactivity in Alzheimer’s patients, supporting continued development of its blood-based diagnostic and ongoing partnership talks,
NEWS | Sep 30, 2026, 09:45 AM UTC
M
Alzinova AB opens rights issue subscription; 79.3% backstopped
Alzinova AB’s rights issue subscription period runs Sep 22–Oct 6, 2026, with coverage of about 79.3% via SEK 0.5M subscription commitments and an SEK 40.0M underwriting commitment.
EQUITY | Sep 22, 2026, 06:31 AM UTC
M
Alzinova starts ALZ-101 Phase II and launches ~$5.5M rights issue
Alzinova began Phase II operational start-up for ALZ-101 in early Alzheimer’s, targeting ~120 patients, with first patient expected around late 2026/early 2027. The company also launched a rights issue of approximately $
EQUITY | Sep 21, 2026, 05:21 PM UTC
L
ALZ - Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need
ALZ - Alzinova Advances Dual Approach to Alzheimer’s Treatment and Diagnosis as World Alzheimer’s Day Highlights Unmet Need
NEWS | Sep 21, 2026, 05:12 PM UTC
L
Alzinova board resolves rights issue of units of about SEK 51 million
The Alzinova board of directors resolved on a rights issue of units of approximately SEK 51 million. The source text includes distribution restrictions but does not add further terms in the provided excerpt.
EQUITY | Sep 10, 2026, 07:10 PM UTC
L
Alzinova initiates Phase 2 operational start-up for ALZ-101
Alzinova AB said it, together with contract research organization Worldwide Clinical Trials, has initiated the operational start-up phase of the Phase 2 study of vaccine candidate ALZ-101 for treatment of Alzheimer’s dis
MACRO | Sep 10, 2026, 07:05 PM UTC